Detalles de la búsqueda
1.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med;
389(11): 1009-1022, 2023 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646702
2.
Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
Br J Clin Pharmacol;
89(1): 316-329, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35981078
3.
Chronic Exposure to Chlorpyrifos Damages Thyroid Activity and Imbalances Hepatic Thyroid Hormones Signaling and Glucose Metabolism: Dependency of T3-FOXO1 Axis by Hyperglycemia.
Int J Mol Sci;
24(11)2023 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37298533
4.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol;
108(1): 73-83, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496096
5.
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Cancer Sci;
111(6): 2116-2122, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297407
6.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol;
20(6): 781-794, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31097405
7.
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Blood;
128(4): 497-503, 2016 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27226434
8.
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Cell Rep Med;
: 101571, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38776914
9.
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Front Oncol;
13: 1271807, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38111533
10.
Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients.
EJHaem;
3(3): 815-827, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36051011
11.
Pax8 and Nkx2-1 haploinsufficiencies differentially affect liver metabolic pathways.
J Endocrinol;
253(3): 115-132, 2022 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35289766
12.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lancet Haematol;
9(11): e822-e832, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36209764
13.
Ovarian Aging: Role of Pituitary-Ovarian Axis Hormones and ncRNAs in Regulating Ovarian Mitochondrial Activity.
Front Endocrinol (Lausanne);
12: 791071, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34975760
14.
Sample-Pooling Strategy for SARS-CoV-2 Detection among Students and Staff of the University of Sannio.
Diagnostics (Basel);
11(7)2021 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34206932
15.
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Leukemia;
35(6): 1722-1731, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32895455
16.
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Leuk Lymphoma;
60(2): 462-470, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30068263
Resultados
1 -
16
de 16
1
Próxima >
>>